Elsevier

Neuroscience Letters

Volume 594, 6 May 2015, Pages 163-168
Neuroscience Letters

Plenary article
The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain

https://doi.org/10.1016/j.neulet.2015.01.084Get rights and content
Under a Creative Commons license
open access

Highlights

  • Gb3 and Lyso-Gb3, plasma lipids accumulating in Fabry disease, cause mechanical allodynia in mice.

  • Lyso-Gb3 elevates intracellular calcium level in sensory neurons.

  • Lyso-Gb3 enhances voltage-dependent calcium currents in small-diameter DRG neurons.

  • Direct effects of lyso-Gb3 on sensory neurons may contribute to the pain of Fabry disease.

Abstract

Fabry disease is an X-linked lysosomal storage disorder characterised by accumulation of glycosphingolipids, and accompanied by clinical manifestations, such as cardiac disorders, renal failure, pain and peripheral neuropathy. Globotriaosylsphingosine (lyso-Gb3), a deacylated form of globotriaosylceramide (Gb3), has emerged as a marker of Fabry disease. We investigated the link between Gb3, lyso-Gb3 and pain. Plantar administration of lyso-Gb3 or Gb3 caused mechanical allodynia in healthy mice. In vitro application of 100 nM lyso-Gb3 caused uptake of extracellular calcium in 10% of sensory neurons expressing nociceptor markers, rising to 40% of neurons at 1 μM, a concentration that may occur in Fabry disease patients. Peak current densities of voltage-dependent Ca2+ channels were substantially enhanced by application of 1 μM lyso-Gb3. These studies suggest a direct role for lyso-Gb3 in the sensitisation of peripheral nociceptive neurons that may provide an opportunity for therapeutic intervention in the treatment of Fabry disease-associated pain.

Abbreviations

Gb3
globotriaosylceramide
Lyso-Gb3
lyso-globotriaosylceramide
GLA
gene encoding alpha galactosidase A
HBSS
HEPES buffered saline
PBS
phosphate buffered saline

Keywords

Pain
Calcium imaging
Voltage-dependent Ca2+ channels
Fabry disease
Dorsal root ganglia

Cited by (0)

1

Equal first authors.

2

Biochemistry Research Group, Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, WC1N 1EH, United Kingdom

3

Janssen Pharmaceutica, Turnhoutseweg 30 2340, Beerse, Belgium